Related Experiment Video

Updated: Jun 17, 2026

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer

Pablo Vivas-Mejia1, Juliana Maria Benito, Ariel Fernandez

  • 1Department of Experimental Therapeutics, Center for RNAi and non-coding-RNA, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|December 24, 2009
PubMed
Abstract

Insights

c-Jun-NH(2)-kinase (JNK)-1 is a promising therapeutic target for ovarian cancer. A novel inhibitor, WBZ_4, demonstrated significant antitumor effects in preclinical models, warranting further clinical investigation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Ovarian carcinoma is a leading cause of cancer-related mortality in women.
  • Identifying novel therapeutic targets is crucial for improving patient outcomes.
  • c-Jun-NH(2)-kinase (JNK)-1 plays a role in cellular processes relevant to cancer progression.

Purpose of the Study:

  • To elucidate the functional, clinical, and biological significance of JNK-1 in ovarian carcinoma.
  • To evaluate the therapeutic potential of a novel JNK inhibitor, WBZ_4, in ovarian cancer models.

Main Methods:

  • Analysis of JNK pathway markers in 116 epithelial ovarian cancer patient samples.
  • In vitro assessment of WBZ_4's effects on ovarian cancer cell lines.
  • In vivo evaluation of WBZ_4 in orthotopic murine models of ovarian cancer, including combination therapy with docetaxel.
  • Validation of JNK-1 inhibition using small interfering RNA (siRNA).

Main Results:

  • A significant association was found between phosphorylated JNK (pJNK) and progression-free survival in ovarian cancer patients.
  • WBZ_4 exhibited dose-dependent inhibition of cell growth and induction of apoptosis in ovarian cancer cell lines.
  • WBZ_4 demonstrated significant tumor growth inhibition in vivo, unlike imatinib, and enhanced efficacy when combined with docetaxel.
  • Systemic administration of JNK-1 siRNA led to reduced tumor weights, confirming JNK-1's role in tumor growth.

Conclusions:

  • JNK-1 represents a viable therapeutic target for ovarian carcinoma.
  • The novel JNK inhibitor WBZ_4 shows promise for clinical development in ovarian cancer treatment.

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...